In this new role, Storrer, who joined Strand in July 2014 as president of North America, will oversee the company's operations worldwide with a focus on strategy and business expansion.

In addition, Strand introduced its US management team, which is focused on the national launch of StrandAdvantage.

Available now to physicians, StrandAdvantage was designed to accelerate the analysis of therapeutically actionable cancer genes and match them to relevant FDA-approved targeted cancer therapies and open clinical trials without the need for multiple tests.

Utilizing proprietary advanced analytics and interpretation expertise, StrandAdvantage provides oncologists with clinically actionable results in days instead of weeks to enable more timely decisions about the best-targeted therapies for patients.

"Scott has been an integral member of the team bringing StrandAdvantage to market in the United States," said Dr Vijay Chandru, chairman & CEO, Strand Life Sciences. "The team we have appointed will support his efforts to deliver precision medicine to more oncologists and pathologists."

Mr Storrer is a 20-year healthcare industry veteran. Prior to joining Strand, he was president and CEO of Genomind, a personalized medicine company.

Before this, he held several leadership positions with Cardinal Health, where he advanced to group president of Cardinal's $81 billion pharmaceutical segment.

Earlier in his career, Mr Storrer was executive vice president, service and information technology with CIGNA Corp.

He holds a bachelor's degree in economics and mathematics from DePauw University and an MBA. from Boston University.

Mr Storrer added: "The team we are putting in place enables Strand to continue to lead advances in NGS approaches to genomic testing and to offer physicians the most advanced care options through precision medicine."